BMO Capital Starts Radient Pharmaceuticals (RPC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailGet Alerts RPC Hot Sheet
Price: $8.27 +0.61%
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Join SI Premium – FREE
BMO Capital initiates coverage on Radient Pharmaceuticals (NYSE: RPC) with a Outperform rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Radient Pharmaceuticals click here. For more ratings news on Radient Pharmaceuticals click here.
Shares of Radient Pharmaceuticals closed at $0.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank resumes coverage of Aritzia with Sector Outperform rating, $175 target
- BMO Capital on Travelers (TRV) as shares turn positive: 'Higher-than-expected buybacks should raise forward EPS estimates'
- CIBC Starts NRG Energy (NRG) at Outperformer
Create E-mail Alert Related Categories
New CoverageRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
